Cryptococcal meningitis

被引:240
作者
Bicanic, T [1 ]
Harrison, TS [1 ]
机构
[1] St George Hosp, Sch Med, Dept Cellular & Mol Med, Div Infect Dis, London SW17 0RE, England
关键词
D O I
10.1093/bmb/ldh043
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cryptococcal meningitis is a common opportunistic infection in AIDS patients, particularly in Southeast Asia and Africa. Cases also occur in patients with other forms of immunosupression and in apparently immunocompetent individuals. Mortality from HIV-associated cryptococcal meningitis remains high (10-30%), even in developed countries, because of the inadequacy of current antifungal drugs and the complication of raised intracranial pressure. In cohorts of HIV-infected patients from sub-Saharan Africa, cryptococcosis has accounted for 13-44% of all deaths. Optimal current therapy is with amphotericin B 0.7-1 mg/kg/day plus flucytosine 100 mg/kg/day for 2 weeks, followed by fluconazole 400 mg/day for 8 weeks and 200 mg/day thereafter. Saline loading reduces amphotericin B nephrotoxicity. If there is no contraindication on CT head scan, repeat lumbar puncture with drainage of cerebrospinal fluid (CSF) is recommended for patients with very raised CSF opening pressure. Expansion of antiretroviral programmes raises the prospect of transforming the long-term prognosis of these patients, provided that they survive the acute phase of the illness. Studies are needed to define more fungicidal drug regimens and to improve the treatment of raised intracranial pressure.
引用
收藏
页码:99 / 118
页数:20
相关论文
共 73 条
  • [11] Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection
    Dadachova, E
    Nakouzi, A
    Bryan, RA
    Casadevall, A
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (19) : 10942 - 10947
  • [12] AMPHOTERICIN-B AS PRIMARY THERAPY FOR CRYPTOCOCCOSIS IN PATIENTS WITH AIDS - RELIABILITY OF RELATIVELY HIGH-DOSES ADMINISTERED OVER A RELATIVELY SHORT-PERIOD
    DELALLA, F
    PELLIZZER, G
    VAGLIA, A
    MANFRIN, V
    FRANZETTI, M
    FABRIS, P
    STECCA, C
    [J]. CLINICAL INFECTIOUS DISEASES, 1995, 20 (02) : 263 - 266
  • [13] British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections
    Denning, DW
    Kibbler, CC
    Barnes, RA
    [J]. LANCET INFECTIOUS DISEASES, 2003, 3 (04) : 230 - 240
  • [14] ELEVATED CEREBROSPINAL-FLUID PRESSURES IN PATIENTS WITH CRYPTOCOCCAL MENINGITIS AND ACQUIRED-IMMUNODEFICIENCY-SYNDROME
    DENNING, DW
    ARMSTRONG, RW
    LEWIS, BH
    STEVENS, DA
    [J]. AMERICAN JOURNAL OF MEDICINE, 1991, 91 (03) : 267 - 272
  • [15] Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model
    Devi, SJN
    [J]. VACCINE, 1996, 14 (09) : 841 - 844
  • [16] PROGNOSTIC FACTORS IN CRYPTOCOCCAL MENINGITIS - STUDY IN 111 CASES
    DIAMOND, RD
    BENNETT, JE
    [J]. ANNALS OF INTERNAL MEDICINE, 1974, 80 (02) : 176 - 181
  • [17] TREATMENT OF CRYPTOCOCCAL MENINGITIS WITH COMBINATION AMPHOTERICIN-B AND FLUCYTOSINE FOR 4 AS COMPARED WITH 6 WEEKS
    DISMUKES, WE
    CLOUD, G
    GALLIS, HA
    KERKERING, TM
    MEDOFF, G
    CRAVEN, PC
    KAPLOWITZ, LG
    FISHER, JF
    GREGG, CR
    BOWLES, CA
    SHADOMY, S
    STAMM, AM
    DIASIO, RB
    KAUFMAN, L
    SOONG, SJ
    BLACKWELDER, WC
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (06) : 334 - 341
  • [18] Antifungal pharmacodynamics: Review of the literature and clinical applications
    Dodds, ES
    Drew, RH
    Perfect, JR
    [J]. PHARMACOTHERAPY, 2000, 20 (11): : 1335 - 1355
  • [19] Serum cryptococcal antigen in patients with AIDS
    Feldmesser, M
    Harris, C
    Reichberg, S
    Khan, S
    Casadevall, A
    [J]. CLINICAL INFECTIOUS DISEASES, 1996, 23 (04) : 827 - 830
  • [20] Management of elevated intracranial pressure in patients with cryptococcal meningitis
    Fessler, RD
    Sobel, J
    Guyot, L
    Crane, L
    Vazquez, J
    Szuba, MJ
    Diaz, FG
    [J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1998, 17 (02): : 137 - 142